XNK Therapeutics

Pharmaceutical ManufacturingStockholm, Sweden11-50 Employees

XNK Therapeutics is a clinical-stage biotechnology company focused on developing personalized cancer therapies based on a patient's own natural killer (NK) cells. Its program spans hematological malignancies and solid tumors, targeting areas with high unmet medical need. Its lead candidate, evencaleucel, is being evaluated in a phase II study that combines the NK cell therapy with the CD38-targeting antibody isatuximab as consolidation after stem cell transplantation in newly diagnosed multiple myeloma. The company operates a proprietary development platform and a GMP facility, and it is co-located with the Karolinska Institute and the Karolinska University Hospital to support its scientific and clinical work. XNK aims to bring autologous NK cell–based therapies to cancer patients worldwide.

Based in Huddinge in the Stockholm region of Sweden, XNK maintains a relatively small, specialized team led by NK cell experts. The company pursues collaborations with clinical institutions to advance its pipeline, including a 2023 research collaboration with Karolinska University Hospital to study acute myeloid leukemia. This setting positions XNK within the niche of cell-based oncology therapeutics, focused on translating autologous NK cell therapies from the lab to patients.

Sign up for free to view info

Email Format Employee directory